Advertisement

Topics

Delcath Systems Company Profile

04:07 EDT 25th September 2017 | BioPortfolio

Our objective is to establish the use of the Delcath system as the standard technique for delivering chemotherapy agents to the liver and to expand the Delcath technology so that it may be used in the treatment of other liver diseases and of cancers in other parts of the body. Our strategy includes the following: Complete clinical trials to obtain FDA approval for the Delcath system with doxorubicin to treat malignant melanoma that has spread to the liver. Our highest priority is completing the Phase III clinical trials, data preparation, statistical analysis and regulatory documents associated with an application for approval of commercial sale of the Delcath system in the United States. Obtain approval to market the Delcath system in the United States for the treatment of other forms of liver cancer using other chemotherapy agents. In addition to researching the use of other chemotherapeutic agents with the Delcath system to treat cancer, we plan to research the use of other compounds with the Delcath system to treat other diseases, such as hepatitis. Our timing to begin these studies will depend on our ability to establish strategic alliances with pharmaceutical manufacturers or other strategic partners in conjunction with our research into other therapeutic compounds or raise additional funds for these purposes. Additional FDA approvals will be required to market the Delcath system for these uses. Introducing the Delcath system into foreign markets. We will seek to establish strategic relationships with domestic and foreign firms that have recognized presence or experience in foreign markets that we intend to target. Our strategy is to focus on markets that have a high incidence of liver cancer and the means to provide and pay for cancer treatments. According to the World Health Organization, many Asian and European countries, including China, Japan, Hong Kong, the Philippines, France, Germany, Italy and Spain, have a higher incidence of liver cancer than the United States. We intend to seek to enter into arrangements with strategic partners who have experience with obtaining regulatory approval or marketing medical devices in those markets. Similarly, we will target countries with a high incidence of cancers that are known to metastasize to the liver, such as melanoma (Australia) and colorectal cancer (Southern Europe). Reduce the cost of the Delcath system’s filtration system. The filters we currently use to detoxify blood outside the body comprise a significant portion of the cost of the Delcath system kit. We are researching technologies which may enable filters to be produced at a lower cost. Leverage our core double balloon catheter technology to expand our product offerings to include systems for administering chemotherapy agents in other parts of the body. Early studies have indicated that the same principles employed in liver isolation may be applied to other organs. By modifying the catheter, including the spacing, size and number of the balloons, the Delcath system initially may be adapted for use in treatment of cancers in other areas of the body, including the limbs, kidneys, lungs, and other organs of the abdominal cavity. Future studies may investigate the use of the Delcath system in other organs as well.

Location

1100 Summer Street
3rd Floor
Stamford
Connecticut
06905
United States of America

Contact

Phone: 203-323-8668
Fax: 203-961-0120
Email: info@delcath.com


News Articles [606 Associated News Articles listed on BioPortfolio]

Offering brings in $2M for Delcath Systems

An offering of 2,360 shares of Series B preferred stock has pulled in $2 million for Delcath Systems, a company that is devel -More- 

Delcath Systems, Inc. (DCTH) Short Interest Update

Delcath Systems, Inc. was the target of a significant increase in short interest in August. As of August 15th, there was short interest totalling 59,973,525 shares, an increase of 41.4% from the July ...

Delcath Systems, Inc. (DCTH) Sees Strong Trading Volume

Shares of Delcath Systems, Inc. saw strong trading volume on Wednesday . 147,629,302 shares were traded during mid-day trading, an increase of 40% from the previous session's volume of 105,731,000...

Delcath Systems Announces Adjournment Of Annual Meeting Meeting Scheduled To Reconvene On June 16

NEW YORK, June 05, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH) (the Company) announced today that its 2017 Annual Meeting of Stockholders (the Annual Meeting), scheduled for June 5...

Delcath Systems May Take Off In The Near Future

Delcath Systems: Wait For The Dust To Settle

Delcath Systems: Approval For The 3rd Reverse Stock Split Or Not?

Delcath Systems' Second Attempt At Shareholder Approval For Reverse Split

PubMed Articles [1511 Associated PubMed Articles listed on BioPortfolio]

Principles of Systems Biology, No. 13.

This month: CRISPR flexes its massively parallel muscles (see also this month's editorial), two systems-level properties discovered in yeast, and a host of new tools and synthetic engineered systems.

Understanding Infusion Pumps.

Infusion systems are complicated electromechanical systems that are used to deliver anesthetic drugs with moderate precision. Four types of systems are described-gravity feed, in-line piston, peristal...

Spiking neural P systems with multiple channels.

Spiking neural P systems (SNP systems, in short) are a class of distributed parallel computing systems inspired from the neurophysiological behavior of biological spiking neurons. In this paper, we in...

Guidelines for Developing Successful Short Advanced Courses in Systems Medicine and Systems Biology.

Systems medicine and systems biology have inherent educational challenges. These have largely been addressed either by providing new masters programs or by redesigning undergraduate programs. In contr...

Principles of Systems Biology, No. 17.

This month: understanding spatial arrangements (Süel/Laue/Schweisguth/de Lorenzo), a giant virus sheds light on evolution (Koonin), synthetic systems (Comtet, Wang, Pósfai), and omics tools (Siuzdak...

Clinical Trials [817 Associated Clinical Trials listed on BioPortfolio]

Registry Protocol- Melphalan Percutaneous Hepatic Perfusion for the Treatment of Unresectable Hepatic Malignancy

Collection of Safety, Efficacy and Resource Utilization Information in Patients Who Have Received Melphalan PHP with the Delcath Hepatic Delivery System for the Treatment of Unresectable H...

Postpartum Immediate Contraception in Cesarean Deliveries-Comparison of Two Intrauterine Systems

To compare two intrauterine systems in order to avoid complications originating from short pregnancy interval and undesired pregnancies in the early postpartum period.

Evaluation and Optimization of PB127 Myocardial Perfusion Echocardiography on Ultrasound Systems

The purpose of this clinical trial is to evaluate various commercially available ultrasound systems and to identify imaging parameters to be used with these systems (along with the contras...

Comparative Study of Two Embryo Culture Systems

The centre for Medically-Assisted Procreation (MAP) of Dijon CHU has two high-technology embryo culture systems, with incubation characteristics that are potentially superior to those prov...

Quality Control of CE-Certified Phonak Hearing Aids - 2016_05

A methodical evaluation of new CE-labelled Phonak Hearing Systems is intended to be conducted on hard of hearing participants to grant quality control prior to product launch. The aim of t...

Companies [1315 Associated Companies listed on BioPortfolio]

Delcath Systems, Inc.

Delcath Systems, Inc. is a development stage, specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high d...

Delcath Systems

Our objective is to establish the use of the Delcath system as the standard technique for delivering chemotherapy agents to the liver and to expand the Delcath technology so that it may be used in the...

IXRF SYSTEMS, Inc

IXRF Systems was incorporated on October 1st, 1993 in the state of Texas. The company originally began by upgrading Kevex bulk X-ray Fluorescence systems to modern Windows based systems. It is from ...

Toshiba Corporation

Toshiba Medical Systems Corporation is a leading worldwide provider of medical diagnostic imaging systems and comprehensive medical solutions, such as CT, X-ray and vascular, ultr...

OSI Systems Inc.

OSI Systems, Inc. is a vertically integrated designer and manufacturer of specialized electronic systems and components for critical applications in the homeland security, healthc...

More Information about "Delcath Systems" on BioPortfolio

We have published hundreds of Delcath Systems news stories on BioPortfolio along with dozens of Delcath Systems Clinical Trials and PubMed Articles about Delcath Systems for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Delcath Systems Companies in our database. You can also find out about relevant Delcath Systems Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...

Skin cancers
There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Basal cell carcinoma Basal cell carcinoma, or BCC, is a cancer of the basal cells at the bottom of the epidermis. It’s very common ...


Corporate Database Quicklinks



Searches Linking to this Company Record